Adding chemo to immunotherapy for advanced lung cancer with large tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding platinum-based chemotherapy to the immunotherapy drug tislelizumab helps people with advanced non-small cell lung cancer that has high PD-L1 levels and at least one large tumor. It is for people who have not had treatment before and cannot have curative surgery or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage IV) non-small cell lung cancer that has spread.
- Your cancer has not been treated yet.
- Your cancer cells show a high level of PD-L1 (50% or more).
- You have at least one tumor or metastasis that is 5 cm or larger.
- Your cancer does not have a gene change that can be targeted with another drug.
- You are healthy enough to receive chemotherapy and immunotherapy together.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the immunotherapy drug Tislelizumab to standard chemotherapy can shrink stage III non-small cell lung cancer that cannot be surgically removed at first. The goal is to see if this combination makes the cancer small enough for surgery.
This study tests a combination of three treatments—an immunotherapy drug called tislelizumab, chemotherapy, and a procedure called BACE—for advanced lung cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
This study tests a combination of tislelizumab (a type of immunotherapy) with chemotherapy, with or without radiation, for people with small cell lung cancer that has spread to only a few places in the body. The goal is to see if this combination helps control the cancer better.
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.